4 Reasons Social Security Is In Trouble - Will You Be, Too?
Worst Things to Buy Before Your Kid Heads Back to School
Monkeys' Behavior Reveals Hidden Threat to Our Wealth
Can Apple Restore the Luster of the iPad?
7 Biotechnology Stocks to Buy Now
4 Top Biotechs Expected to Beat Earnings Expectations
8 Biotechnology Stocks to Buy Now
Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics
Pharmacyclics has several positive catalysts, says RBC Capital
Pharmacyclics' CEO Discusses Q1 2014 Results - Earnings Call Transcript
Pharmacyclics downgraded to Neutral from Overweight at Piper Jaffray
Pharmacyclics sees Q2 net product revenue $80M, plus or minus 5%
Pharmacyclics reports Q1 Imbruvica sales $42.6M, Q1 product revenue $56.18M